SCOTLAND’s leading Alzheimer’s clinical research centre, Glasgow Memory Clinic, has unveiled its new brand name, NeuroClin, and plans to further expand its services following an eight-figure investment.
West of Scotland-based Glasgow Memory Clinic will now be known as a NeuroClin centre, paving the way for the organisation to open more centres across the UK and expand its areas of clinical research into other neurological conditions.
NeuroClin today confirms its new Chair as highly experienced global pharma executive Jeff Thomis, bringing decades of experience in drug discovery, clinical development and commercialisation. Jeff played a major role in the development and registration of a number of novel drugs at Bristol-Myers Squibb and was President of Global Clinical Development Services at Quintiles. He has been the Chair of several pharma service companies and is currently on the Board of NASDAQ listed ThermoGenesis.
Chair, Jeff Thomis, said: “I am absolutely delighted to be working with Glasgow Memory Clinic which is a leading global centre and a pioneer for the conduct of Alzheimer’s clinical studies. Now with the expansion into other areas of neurology, from our new clinic and the planned opening of other locations, it is a very exciting time for us on our journey to expand our expertise in other areas of neurology clinical research. We have assembled a strong management team that is supported by private equity investment to ensure our continued high quality and growth.”
Founded in 1999, Glasgow Memory Clinic has over the years contributed significantly to many high-quality research projects. With the substantial investment now made at its new Eurocentral HQ it is further strengthening its position as a centre of excellence in clinical research and development in neurodegenerative diseases.
Find out more about NeuroClin at www.neuroclin.com
